glp 1 approved for mash The FDA has Wegovy (semaglutide) as a treatment metabolic-associated steatohepatitis (MASH) with moderate-to-advanced scarring, a serious liver condition affecting approximately 6% of US adults. Key highlights of drug development program GLP-1 BREAKTHROUGH: FDA APPROVES TREATMENT

This medication category includes weekly injectables and daily oral pills: Semaglutide (Wegovy , Ozempic ) Tirzepatide (Zepbound , Mounjaro ) Orforglipron (Foundayo ) The FDA approves these specific brands for different uses: Wegovy , Zepbound , and Foundayo for weight management, and Ozempic and Mounjaro for type 2 diabetes

Important 2026 Update Because BCBS is a national federation of independent, locally operated companies, coverage can vary widely across states and plans

Diabetes Obes Metab 2013;15:15-27.PubMed 26

CREDITS Agency: Ronin Labs Executive Creative Director: Amit Basak Creative Director: Girija Naiksatam Producer: Nachiket Bohra Art Director: Abhishek Kumar Director: Edwin Quadros